International Stem Cell (ISCO) Common Equity (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Common Equity of -$4.1 million for Q4 2025, down 3.31% year-over-year from -$4.2 million in Q4 2024, and down 7.52% quarter-over-quarter from -$3.8 million in Q3 2025.
International Stem Cell (ISCO) Common Equity (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Common Equity for 16 consecutive years, with -$4.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 3.31% year-over-year to -$4.1 million; the TTM figure through Dec 2025 stood at -$4.1 million (down 3.31% YoY), while the FY2025 annual figure was -$4.1 million, down 3.31% from the prior year.
- Common Equity fell to -$4.1 million in Q4 2025 per ISCO's latest filing, from -$3.8 million in the prior quarter.
- Across five years, Common Equity topped out at -$3.8 million in Q3 2025 and bottomed at -$4.7 million in Q1 2021.
- Historically, Common Equity has averaged -$4.2 million across 5 years, with a median of -$4.2 million in 2023.
- Annual changes were most pronounced in 2021 — Common Equity sank 65.25% — and 2023, when it climbed 17.05%.
- International Stem Cell's Common Equity stood at -$4.6 million in 2021, then grew by 1.48% to -$4.5 million in 2022, then gained by 7.37% to -$4.2 million in 2023, then climbed by 6.14% to -$3.9 million in 2024, then retreated by 3.31% to -$4.1 million in 2025.
- Business Quant data shows ISCO's Common Equity at -$4.1 million in Q4 2025, -$3.8 million in Q3 2025, and -$3.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | -4.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.23 Mn |
| Dec 31, 2025 | -4.06 Mn |
| Sep 30, 2025 | -3.78 Mn |
| Jun 30, 2025 | -3.90 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | -3.93 Mn |
| Sep 30, 2024 | -4.04 Mn |
| Jun 30, 2024 | -4.02 Mn |
| Mar 31, 2024 | -4.26 Mn |
| Dec 31, 2023 | -4.19 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | -3.85 Mn |
| Mar 31, 2023 | -4.45 Mn |
| Dec 31, 2022 | -4.52 Mn |
| Sep 30, 2022 | -4.65 Mn |
| Jun 30, 2022 | -4.42 Mn |
| Mar 31, 2022 | -4.51 Mn |
| Dec 31, 2021 | -4.59 Mn |
| Sep 30, 2021 | -4.36 Mn |
| Jun 30, 2021 | -4.31 Mn |